-
1 Comment
Hospital Corporation of China Limited is currently in a long term downtrend where the price is trading 3.5% below its 200 day moving average.
From a valuation standpoint, the stock is 95.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.6.
Hospital Corporation of China Limited's total revenue rose by 8.0% to $219M since the same quarter in the previous year.
Its net income has increased by 90.3% to $131M since the same quarter in the previous year.
Finally, its free cash flow fell by 51.0% to $11M since the same quarter in the previous year.
Based on the above factors, Hospital Corporation of China Limited gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| ISIN | KYG4612W1042 |
| Industry | Medical Care Facilities |
| Exchange | HK |
| CurrencyCode | HKD |
| Market Cap | 939M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | -0.3 |
| Dividend Yield | None |
Hospital Corporation of China Limited, an investment holding company, operates and manages hospitals in the People's Republic of China. The company operates through three segments: General Hospital Services; Hospital Management Services; and Sale of Pharmaceutical Products. The company provides inpatient and outpatient, management, supply chain, and other ancillary services to certain hospitals; and property management services. It engages in the wholesale of pharmaceutical products and medical consumables. The company was incorporated in 2014 and is headquartered in Beijing, the People's Republic of China. Hospital Corporation of China Limited is a subsidiary of Vanguard Glory Limited.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 3869.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
